Are you Dr. Zojwalla?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 58 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
161 Fort Washington Ave
New York, NY 10032Phone+1 212-305-5056- Is this information wrong?
Summary
- Dr. Naseem Zojwalla, MD is an oncologist in New York, New York. She is currently licensed to practice medicine in New York.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2002 - 2005
Temple University HospitalResidency, Internal Medicine, 1998 - 2001
Lewis Katz School of Medicine at Temple UniversityClass of 1998
Certifications & Licensure
NY State Medical License Active through 2013
Clinical Trials
- A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies Start of enrollment: 2006 Jan 01
- Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma Start of enrollment: 2007 Sep 01
Publications & Presentations
PubMed
- 24 citationsBelzutifan, a Potent HIF2α Inhibitor, in the Pacak-Zhuang Syndrome.Junne Kamihara, Kayla V. Hamilton, Jessica A. Pollard, Catherine Clinton, Jill A. Madden, Jasmine Lin, Alma Imamovic, Catherine B. Wall, Ari J. Wassner, Brent R. Weil,...> ;The New England Journal of Medicine. 2021 Nov 25
- 2 citationsAuthor Correction: Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysisToni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, San...> ;Nature Medicine. 2021 Aug 27
- 126 citationsInhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Toni K. Choueiri, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. McDermott, M. Dror Michaelson, Leonard Joseph Appleman, San...> ;Nature Medicine. 2021 Apr 22
- Join now to see all
Press Mentions
Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022- Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022
- Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical OfficerJanuary 31st, 2022
- Join now to see all
